Drug intelligence / Profile preview

C8C8

Development stage: Preclinical
Lead developer: EsoCap
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Esophageal

Overview

C8C8 is an anti-BMP (Bone Morphogenetic Protein) monoclonal antibody being developed by EsoCap, under an exclusive worldwide licensing agreement with Upadia. It has demonstrated preclinical efficacy in inhibiting the development of Barrett's esophagus. EsoCap plans to combine C8C8 with its proprietary thin-film drug delivery platform to enable prolonged, local application directly to the esophagus, aiming to provide a non-invasive treatment for this pre-cancerous condition.

Targets

BMP4 (Bone morphogenetic protein 2)BMP2 (Bone morphogenetic protein 2)

Beyond the preview

Go deeper on C8C8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C8C8.

Explore the full profile